TY - JOUR
T1 - A meta-analysis comparing the risk of metastases in patients with rectal cancer and MRI-detected extramural vascular invasion (mrEMVI) vs mrEMVI-negative cases
AU - Siddiqui, Muhammed R.S.
AU - Simillis, Constantinos
AU - Hunter, Chris
AU - Chand, Manish
AU - Bhoday, Jemma
AU - Garant, Aurelie
AU - Vuong, Te
AU - Artho, Giovanni
AU - Rasheed, Shahnawaz
AU - Tekkis, Paris
AU - Abulafi, Al Mutaz
AU - Brown, Gina
N1 - Funding Information:
This project was supported by the National Institute for Health Research RM/ICR Biomedical Research Centre and Lisa Scerri, and McGill University and Hospital for access to raw data.This project was supported by the National Institute for Health Research RM/ICR Biomedical Research Centre and Lisa Scerri, and McGill University and Hospital for access to raw data.
Publisher Copyright:
© 2017 The Author(s).
PY - 2017/6/6
Y1 - 2017/6/6
N2 - Background:Pathological extramural vascular invasion (EMVI) is an independent prognostic factor in rectal cancer, but can also be identified on MRI-detected extramural vascular invasion (mrEMVI). We perform a meta-analysis to determine the risk of metastatic disease at presentation and after surgery in mrEMVI-positive patients compared with negative tumours.Methods:Electronic databases were searched from January 1980 to March 2016. Conventional meta-analytical techniques were used to provide a summative outcome. Quality assessment of the studies was performed.Results:Six articles reported on mrEMVI in 1262 patients. There were 403 patients in the mrEMVI-positive group and 859 patients in the mrEMVI-negative group. The combined prevalence of mrEMVI-positive tumours was 0.346(range=0.198-0.574). Patients with mrEMVI-positive tumours presented more frequently with metastases compared to mrEMVI-negative tumours (fixed effects model: odds ratio (OR)=5.68, 95% confidence interval (CI) (3.75, 8.61), z=8.21, df=2, P<0.001). Patients who were mrEMVI-positive developed metastases more frequently during follow-up (random effects model: OR=3.91, 95% CI (2.61, 5.86), z=6.63, df=5, P<0.001).Conclusions:MRI-detected extramural vascular invasion is prevalent in one-third of patients with rectal cancer. MRI-detected extramural vascular invasion is a poor prognostic factor as evidenced by the five-fold increased rate of synchronous metastases, and almost four-fold ongoing risk of developing metastases in follow-up after surgery.
AB - Background:Pathological extramural vascular invasion (EMVI) is an independent prognostic factor in rectal cancer, but can also be identified on MRI-detected extramural vascular invasion (mrEMVI). We perform a meta-analysis to determine the risk of metastatic disease at presentation and after surgery in mrEMVI-positive patients compared with negative tumours.Methods:Electronic databases were searched from January 1980 to March 2016. Conventional meta-analytical techniques were used to provide a summative outcome. Quality assessment of the studies was performed.Results:Six articles reported on mrEMVI in 1262 patients. There were 403 patients in the mrEMVI-positive group and 859 patients in the mrEMVI-negative group. The combined prevalence of mrEMVI-positive tumours was 0.346(range=0.198-0.574). Patients with mrEMVI-positive tumours presented more frequently with metastases compared to mrEMVI-negative tumours (fixed effects model: odds ratio (OR)=5.68, 95% confidence interval (CI) (3.75, 8.61), z=8.21, df=2, P<0.001). Patients who were mrEMVI-positive developed metastases more frequently during follow-up (random effects model: OR=3.91, 95% CI (2.61, 5.86), z=6.63, df=5, P<0.001).Conclusions:MRI-detected extramural vascular invasion is prevalent in one-third of patients with rectal cancer. MRI-detected extramural vascular invasion is a poor prognostic factor as evidenced by the five-fold increased rate of synchronous metastases, and almost four-fold ongoing risk of developing metastases in follow-up after surgery.
KW - MRI
KW - extramural vascular invasion
KW - rectal cancer
UR - http://www.scopus.com/inward/record.url?scp=85020401080&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85020401080&partnerID=8YFLogxK
U2 - 10.1038/bjc.2017.99
DO - 10.1038/bjc.2017.99
M3 - Article
C2 - 28449006
AN - SCOPUS:85020401080
SN - 0007-0920
VL - 116
SP - 1513
EP - 1519
JO - British Journal of Cancer
JF - British Journal of Cancer
IS - 12
ER -